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Chloroplast transformation in the photosynthetic alga Chlamydomonas reinhardtii has been used to explore the
potential to use it as an inexpensive and easily scalable system for the production of therapeutic recombinant
proteins. Diverse proteins, such as bacterial and viral antigens, antibodies and, immunotoxins have been successfully
expressed in the chloroplast using endogenous and chimeric promoter sequences. In some cases, proteins have
accumulated to high level, demonstrating that this technology could compete with current production platforms.
This review focuses on the works that have engineered the chloroplast of C. reinhardtii with the aim of producing
recombinant proteins intended for therapeutical use in humans or animals.
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For centuries, algae have been used for human and ani-
mal consumption (Spolaore et al. 2006). More recently
algae have been cultivated for the production of fatty
acids, secondary metabolites such as pigments, color-
ants, and bioactive compounds with antitumor, antiviral,
and antifungal activities (Borowitzka 1999; Singh et al.
2005; Spolaore et al. 2006). Despite the high number of
algae species estimated to populate the planet (Guiry
2012), only a handful of them are currently used with
commercial success. The main species cultivated for hu-
man or animal consumption are Chlorella and Spirulina,
while Dunaliella salina and Haematococcus pluvialis
have been cultured for the extraction of β-carotene and
astaxanthin, respectively (Borowitzka 1999).
High demand and low productivities are driving the ef-
forts in algal technology towards the development of
genetically engineered strains. At the top of the list of
the algae species that have been genetically modified
comes Chlamydomonas reinhardtii, an alga that has
been used for a long time as a model for the study of
photosynthesis, cell motility, phototaxis, and cell wall* Correspondence: jbadilloc@ipn.mx
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reproduction in any medium, provided the origbiogenesis among other genetic and metabolic processes
(Harris 2001). Transformation protocols exist for the
genetic modification of the nucleus (Kindle 1990), the
mitochondria (Remacle et al. 2006), and the chloroplast
(Boynton et al. 1988). All three compartments have been
genetically engineered with different purposes but it has
been the chloroplast which has received considerable
attention, mainly to demonstrate that the accumulation
of recombinant proteins in this organelle is feasible.
Chloroplast transformation is carried out using a particle
bombardment device as schematised in Figure 1. Chloro-
plast transformation technology has demonstrated that not
only could it compete with current production platforms
but it would be better suited for the production of some
proteins such as immunotoxins (Tran et al. 2013a; Tran
et al. 2013b), non glycosilated antigens (Gregory et al. 2012;
Gregory et al. 2013), and antibodies (Mayfield et al. 2003;
Tran et al. 2009) which have been difficult to produce in
other systems. This review will comment on the most rep-
resentative cases that have made clear that chloroplast
transformation technology to produce therapeutical pro-
teins is beyond the proof-of-concept stage.Biopharming in the chloroplast of C. reinhardtii
Biopharming refers to the technology that aims, through
the use of genetic engineering or, more recently, syn-
thetic biology, to produce health-related products sucher. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and




Figure 1 Chloroplast transformation in Chlamydomonas reinhardtii. a) Introduction of foreign DNA material into the chloroplast of C.
reinhardtii is carried out using a particle bombardment device. The device uses helium gas to accelerate particles towards algae placed at the
interior of a vacuum chamber. b) Gold or tungsten particles are coated with a plasmid carrying the genes of interest (in this case the green
fluorescence protein GFP) and when accelerated penetrate the cells placed on top of selection medium. After a few weeks, transformed cells
proliferate in the presence of a selection antibiotic. c) When the plasmid carrying the genes reaches de chloroplast, genes integrate into the
plastid genome by homologous recombination between regions present in the plasmid (LB and RB) and in the chloroplast genome (CpDNA).
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growth factors, etc. from plants and animals, as op-
posed to the traditional chemical synthesis in the
pharmaceutical industry, the extraction from the nat-
ural source or production in bacteria, yeast or mam-
malian cells (Gimpel et al. 2013; Specht et al. 2010).
Biopharming in plants and algae has several advantages
over bacteria and yeast; three of the most import are:
a) a product that is free of human pathogens and more
quality-consistent; b) larger quantities can be obtained
in a reduced or confined area and; c) low production
cost when organisms are grown in economic media.
Microbes, yeast, and mammalian cells have been ex-
plored to produce therapeutic proteins (Demain and
Vaishnav 2009), in fact, there are products derived from
genetic engineering currently in the market (Leader
et al. 2008). Because C. reinhardtii has many advantages
over other species, it is not surprising that it has alsobeen proposed as a platform for the production of high-
value proteins with therapeutical applications (Specht
et al. 2010). Some of the advantages C. reinhardtii has
include: a fast growth rate compared to plants and
animal cells, it is a Generally Recognized as Safe (GRAS)
organism by the Food and Drug Administration from
the United States of America, cell cultures can be grown
in bioreactors, thus reducing the risk of transgene dis-
persion, or in open raceways without competing with
arable land.
Genetic tools and transformation protocols have been
developed for the chloroplast of C. reinhardtii for the
production of high value molecules for the biotechno-
logical industry (Rosales-Mendoza et al. 2012; Specht
et al. 2010). However, unlike plants, where chloroplast
genetic engineering has been used more widely, for in-
stance, to produce oils, pigments, vitamins, enzymes, or
to make drought and salt tolerant plants (Bock 2014;
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C. reinhardtii has mainly been limited to the production
of proteins with therapeutical applications. In Table 1, a
comprehensive list of the therapeutic proteins produced in
the chloroplast of C. reinhardtii, showing the genetic ele-
ments used for expression and relevant information can be
consulted. Such proteins include: viral and bacterial anti-
gens, antibodies, immunotoxins, and enzymes. In the fol-
lowing section representative cases that have dealt with the
production of these proteins will be discussed. For a more
complete review of chloroplast genetic tools (Bateman and
Purton 2000; Day and Goldschmidt-Clermont 2011), syn-
thetic biology in algae (Georgianna and Mayfield 2012;
Gimpel et al. 2013), and application perspectives (Beer et al.
2009; Gimpel et al. 2013) the reader is invited to consult
the appropriate references.
Antibodies
Demand for antibodies to treat diverse diseases is con-
stantly increasing and is likely to be difficult to meet in
the near future. Antibodies have been difficult to pro-
duce in prokaryotic systems and thus have to be pro-
duced in eukaryotic systems (Makino et al. 2011). Most
of the commercially available antibodies are currently
produced in mammalian cells making the final product
expensive and sometimes scarce (Leader et al. 2008). If
antibodies could be efficiently produced in a photosyn-
thetic organism, price would drop and the product
would be more accessible to developing countries.
Antibodies have been successfully expressed in the
chloroplast of C. reinhardtii. Mayfield et al. (2003) have
expressed a monoclonal antibody directed against a
glycoprotein of the herpes simplex virus D (HSV8).
The antibody was expressed from a large single chain
(lsc) coding sequence, which consisted on the entire
IgA heavy chain protein fused to the variable region of
the light chain by a flexible linker peptide. The expres-
sion of the HSV8-lsc was under the control of the
chloroplast atpA and rbcL promoters. The lsc antibody
accumulated as a soluble protein in transplastomic
strains (that is, strains with a transgenic chloroplast
genome), and was capable of binding to herpes virus pro-
tein D in vitro. The lsc antibodies formed disulphide bonds
and assembled as dimers in the chloroplast.
In another successful case of an antibody produced
in C. reinhardtii chloroplast, (Tran et al. 2009) have
demonstrated that a monoclonal antibody against a
protein from Bacillus anthracis could be assembled
into a functional tetrameric structure consisting on 2
heavy-chain and 2 light-chain subunits, capable of
binding the PA83 antigen from the pathogen in vitro.
Affinity was determined for the antibodies produced
by the alga and an antibody expressed in a mammalian
system and were shown to be similar in function. Acomparison with antibody 83K7C, expressed in CHO
cells, which had been demonstrated to provide protec-
tion from anthrax toxicity, in both cell-based assays
and animal models, (Tran et al. 2009) showed that,
apart from the lack of glycosylation (inherent to
chloroplasts), the chloroplast-produced antibody had
the same PA83 binding properties than the antibody
produced in the mammalian cell-line. The antibody
producing strain was reported to be stable and contin-
ued to produce the antibody for more than one year.
Immunotoxins
Immunotoxins, antibodies linked to a proteic toxin, have
found application in cancer treatment as eukaryotic toxins
can be coupled to antibodies with cancer-cell specific bind-
ing affinity, thus targeting the apoptosis-inducing toxin.
Immunotoxins have been difficult to produce in eukaryotic
systems, because due to their nature they kill eukaryotic
cells, and production in bacteria has had limited success
because prokaryotes are unable to fold multiple domain
proteins.
The Stephen Mayfield group at the University of California
San Diego has shown that immunotoxins can be produced
and confined in the chloroplast of C. reinhardtii. A single
chain antibody recognizing the CD22 surface receptor
from B-cells was fused either to domain II and III of Exo-
toxin A from Pseudomonas aeruginosa (Tran et al. 2013b)
or to the ribosome inactivating protein, gelonin, from
Gelonium multiflorm (Tran et al. 2013a). In both cases it
was demonstrated that the immunotoxins were capable of
specifically binding to B-cell in vitro and that in the case of
the immunotoxin Exotoxin A, survival of mice implanted
with a human B-cell tumor, the life-span was extended.
The two reports are the first cases in which entire immuno-
toxins have been produced in eukaryotic cells. This has
been possible because the chloroplast served as a confined
compartment sequestering the eukaryotic toxin from the
cytosol, where it is toxic.
Antigens for vaccination
Of the total deaths in the world, 25% result from infectious
diseases; that number increases to 45% in developing coun-
tries (Arntzen et al. 2005). In humans, vaccination is the
most effective mean of inducing resistance to a certain
pathogen. The World Health Organization (WHO) and the
United Nations Children’s Fund (UNICEF) have empha-
sised the need for new production technologies that can
satisfy the demand for global immunisation (UNICEF;
WHO). They have also made clear that needle-free, heat-
stable, and ease of distribution are important elements for
these vaccines to be cost-benefit acceptable.
If antigens intended for vaccination (subunit vaccination)
could be produced in GRAS organisms, such as C. rein-
hardtii, the purification process would not be concerned
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the process less expensive and the product safer than when
it is obtained from microbial cultures. Furthermore, for cer-
tain applications, whole GRAS organism (lysed or lyophi-
lized) could even be used as vehicles for administration
(Yoon et al. 2011). A few attempts have been made to ex-
press viral or bacterial antigens in the chloroplast of C. rein-
hardtii, for which some examples are given below.
The first subunit viral vaccine produced in the chloro-
plast of C. reinhardtii was the translational fusion of the
structural protein VP1, from the Foot and Mouth Dis-
ease Virus (FMDV), and the cholera toxin B subunit
(CtxB) (Sun et al. 2003). FMD in livestock can be pre-
vented by subunit vaccination. The structural protein
VP1 of FMDV carries critical epitopes, which can induce
neutralizing antibodies while the CtxB is a potent mucosal
adjuvant that can bind to intestinal epithelial surfaces via
GM1 ganglioside receptors. The CtxB-VP1 fusion protein
produced in the chloroplast retained both GM1-ganglioside
binding affinity and antigenicity. The CtxB-VP1 fusion pro-
tein accumulated up to 3% of the total soluble protein
(TSP), a 30-fold increase in comparison with the accumula-
tion level obtained for the same antigen when produced
from the nuclear genome of alfalfa and Arabidopsis
thaliana (Carrillo et al. 1998; Wigdorovitz et al. 1999).
Bacterial antigens have also been shown to accumulate
in the chloroplast of C. reinhardtii (Michelet et al.
2011). Genes acrV and vapA, from Aeromonas salmoni-
cida, an important pathogen causing fish furunculosis
were expressed using the atpA, psbA, and psbD pro-
moters, previously reported to produce high levels of
expression for various transgenes (Rasala et al. 2011).
The genes were also expressed from a newly proposed
promoter, the promoter from gene psaA along with exon
1 from the same gene (PpsaA-exon1). The authors pos-
tulated that, since in wild-type strains the psaA mRNA
is spliced in trans from three separate precursors, the
precursor psaA-exon1 would over-accumulate in mu-
tants defective in psaA transsplicing. The same should
happen to a chimeric mRNA with the PpsaA-exon1.
Furthermore, as the unassembled product of psaA in-
hibits the translation of their own mRNA, in a trans-
splicing-deficient mutant where psaA product cannot be
produced, feedback inhibition would be circumvented,
and the translation of a recombinant protein expressed
under the PpsaA-exon1 would be higher. It was found
that by expressing acrV and VapA from the PpsaA-
exon1 promoter in a nuclear mutant-deficient on the
psaA trans-splicing factor, VapA accumulated to 0.3%
and AcrV to 0.8% total protein (TP). In the case of
VapA, this level was approximately 15 to 30-fold higher
than the level of VapA present in cells where the nuclear
mutation was absent. Even though this increase in the
level of accumulation looks attractive, the fact that thetransgenic lines obtained are non photosynthetic is a
drawback, because, even though lines could be cultivated
with acetate as the only carbon source, costs could be
reduced if lines were simply grown on CO2 and light.
The fact that chloroplasts do not glycosilate proteins
might be seen as a drawback. However, this characteris-
tic has been exploited positively for certain proteins,
(Gregory et al. 2013) have successfully expressed the
structurally complex non-glycosilated proteins Pfs25 and
Pfs28 from Plasmodium falciparum, the parasite respon-
sible of malaria. Proteins accumulated to levels of 0.2-
0.5% TSP when expressed from the psbA promoter in
photosynthetic deficient strains. It has been suggested
that Pfs25 and Pfs28 could be used to generate anti-
bodies that bind, and neutralize them in vivo, thus pre-
venting the formation of P. falciparum sporozoites in
the mosquitos, which are ultimately responsible for the
transmission of the parasite to humans. Producing these
proteins in other systems has been difficult as diverse
conformations occur and the proteins are glycosylated
when produced in eukaryotic systems whilst native Pfs25
and Pfs28 from the parasite are not. When produced in
the chloroplast, proteins folded correctly, lacked glyco-
sylation, and generated antibodies that blocked the
transmission of the parasite by preventing the formation
of the sporozoites in the mosquito in vitro. This shows
the fitness of the C. reinhardtii chloroplast for the ex-
pression of properly folded complex proteins.
Oral delivery of chloroplast-produced antigens
The use of whole lyophilized algae as a vehicle to orally
administer biologically active proteins has also been
demonstrated, even if only for a limited number of cases.
The D2 fribronectin-binding domain from Staphylococ-
cus aureus (Georgianna and Mayfield 2012) and the
transmission blocking Pfs25 antigen from Plasmodium
falciparum, the causative agent of malaria (Gregory et al.
2013), have been shown to elicit systemic and mucosal
responses when fed to mice in a lyophilized powder of
algae. The idea that algae expressing antigens could be
administered orally seems very attractive because pre-
sumably the production of IgG and IgA antibodies could
be induced and hence confer protection to the animal or
person vaccinated.
In the case of the D2 fribronectin-binding domain
from S. aureus, specific mucosal (measured by the pres-
ence of IgA antibodies) and systemic (measured by the
presence of IgG antibodies) immune responses were
demonstrated following oral delivery of lyophilized algae
expressing the D2 protein. Furthermore, immunized
mice were able to reduce pathogen load when S. aureus
was inoculated in the intestine and the spleen.
In the case of Pfs25 from P. falciparum, when it was
translationally fused to CtxB and administered orally
Table 1 Overview of recombinant proteins produces in the chloroplast of Chlamydomonas reinhardtii
Recombinant therapeutic protein Yield Relevant information Reference
VP1-CTB; Protein VP1 from foot and mouth




Demonstrated that the C. reinhardtii chloroplast
derived VP1-CTB could bind to GM1-ganglioside
receptor in vitro
(Sun et al. 2003)
HSV-lsc; Large single chain (lsc) antibody
directed against glycoprotein D protein
from Herpes simplex virus (HSV)
Not reported First report to show that the C. reinhardtii
chloroplast can efficiently fold antibodies and form
disulfide bonds
(Mayfield et al. 2003)
TRAIL; Tumor necrosis factor-related
apoptosis-inducing ligand
0.43%-0.67% TSP (Yang et al. 2006)
M-SAA; Mammary-associated serum amyloid 3%-5% TSP M-SAA was shown to generate mucin induction in
a human intestinal epithelial cell line. Demonstrated
that the psbA promoter yields high level or
recombinant protein accumulation when the
endogenous psbA gene is absent
(Manuell et al. 2007)
CSFV-E2; Classical swine fever virus (CSFV)
structural protein E2
1.5-2% TSP Subcutaneous immunization of mice with E2 was
shown to induced IgG antibodies
(He et al. 2007)
Human glutamic acid decarboxylase (hGAD65) 0.25-0.3% TSP The protein was shown to immunoreact with sera
from diabetic mice
(Wang et al. 2008)




This report looked at the expression of 11 proteins.
Nine proteins showed some level of accumulation,
while the rest could not be detected. It showed
that there are variations in the level of expression
even amongst lines obtained with the
transformation construct. Authors postulated the
existence of the transformosome, a state in which
particular genomic characteristics, induced
incidentally with transformation, affect, negatively or
positively, the expression of the transgene
(Surzycki et al. 2009)
IHNV-G; Infectious haematopoietic necrosis virus < 0.5% TCP
IPNV-VP2; Infectious pancreatic necrosis virus < 0.3% TCP
VP2 protein 1-0.1% TCP
IPNV-VP2 SBC; Infectious pancreatic necrosis
virus
1-0.2% TCP
Quorum sensing-regulated gene (LecA) p57 < 0.5 TCP
PCV2; Porcine circovirus type 2 0.9-0.2% TCP
VP-2C < 0.5% TCP
VP28 21-0.2% TCP
HC-83K7C; Heavy chain human monoclonal
antibody against anthrax protective antigen 83
(PA83)
0.01% dwt It was shown that the heavy and light chains
expressed in trans could assembled into a
fully-functional monoclonal antibody against PA83
(Tran et al. 2009)
LC-83K7C; Light chain human monoclonal
antibody against anthrax PA83
CTB-D2; D2 fibronectin-binding domain of
Staphylococcus aureus fused to the cholera toxin
B subunit
0.7% TSP First report to show that an orally-administered alga
expressing an antigen in the chloroplast triggers a
mucosal and systemic immune response in mice
(Dreesen et al. 2010)
14FN3; Domain 14 of human fibronectin 3%-0.15% TSP This report looked at the expression of seven
therapeutic proteins. For three of the proteins, a
level of accumulation above 1% was observed,
whereas for the rest of the proteins, erythropoietin,
interferon β, and proinsulin no protein was
detected. Biological activity was evaluated for VEGF
and HMGB1
(Rasala et al. 2010)
VEGF; Human vascular endothelial growth factor 2%-0.1% TSP
HMGB1; High mobility group protein B1 2.5%-1% TSP
acrV2 and vapA2; antigens from the fish
pathogen Aeromonas salmonicida
0.8% and 0.3% TP
respectively
Showed that the psaA promoter-exon1 element can
be used to drive the expression of foreign genes in
non-photosynthetic strains
(Michelet et al. 2011)
Escherichia coli phytase gene (appA) N.D. This study showed that algae expressing a bacterial
phytase gene in the chloroplast could be
lyophilized and administered orally to broiler chicks.
The enzyme was active in the gut and reduce the
fecal excretion of phytate.
(Yoon et al. 2011)




First report to show that Pfs25 and Pfs28 can be
produced without glycosilation and in a correct
conformation recognized by monoclonal antibodies
specific to conformational epitopes
(Gregory et al. 2012)
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Table 1 Overview of recombinant proteins produces in the chloroplast of Chlamydomonas reinhardtii (Continued)
αCD22PE40; monomeric immunotoxin
consisting on the single chain antibody that
recognizes the CD22 surface protein from
B-cells, fused to domains II and III of exotoxin
A (PE40) from Pseudomonas aeruginosa
0.3%-0.4% TSP First report to show that immunotoxins can be
produced in an eukaryotic system without being
toxic to the cell.
(Tran et al. 2013b)
αCD22HCH23PE40; dimeric version of
αCD22PE40
0.2%-0.3% TSP
CtxB-Pfs25; Plasmodium falciparum surface
protein 25 fused to the β subunit of the cholera
toxin from Vibrio cholera
0.09% TSP Demonstrated that the fusion protein can induced
IgA antibodies when administered orally as part of a
lyophilized powered. However, IgG antibodies could
not be elicited with this route of administration
(Gregory et al. 2013)
αCD22Gel; single chain antibody targeting the
CD22 receptor from B-cells, fused to the
eukaryotic ribosome inactivating protein,
gelonin, from Gelonium multiflorm
0.2%-0.3% TSP Demonstrated that immunotoxin can efficiently
bind to cancerous B-cells in vitro and kill them
without affecting non B-cells
(Tran et al. 2013a)
αCD22CH23Gel; dimeric version of αCD22Gel 0.1% - 0.2% TSP
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bodies against CtxB and Pfs25 were detected but no IgG
antibodies against Pfs25 (Gregory et al. 2013). This could
have been the result of CtxB not being the most appro-
priate adjuvant for oral vaccination with Pfs25. In con-
trast, it had been previously demonstrated that when
Psf25 was purified and injected into mice an IgG re-
sponse was observed (Gregory et al. 2012). If other adju-
vants can perform better than CtxB in conjunction with
Pfs25 or if some antigen will simply not elicit an im-
mune response when administered orally remains to be
investigated.
Even though, these two cases clearly demonstrate that it
could be possible to lyophilize algae expressing antigens
and use the powder as a vehicle to administer antigens or-
ally, further studies are needed to demonstrate the safety
and efficacy of a broader number of antigens. It has been
suggested that vaccines produced in edible organisms such
as plants, algae or yeast could potentially be administered
orally, however, it is not clear yet how dosage could be
controlled consistently. Freeze-drying the product could
help solve this problem, as the concentration would be
easier to determine in a powder (Gregory et al. 2013). An-
tigens in lyophilized algae have been shown to be stable at
room temperature over a period of months (Dreesen et al.
2010; Gregory et al. 2013). A powder that is stable at room
temperature may help overcome the problems associated
with the cold chain in the distribution of vaccines in de-
veloping countries.
Other therapeutic proteins
In the first report of a recombinant mammalian protein
produced in algae, and one of the highest level of protein
accumulation yet reported for the chloroplast of C.reinhardtii, (Manuell et al. 2007) have demonstrated that it
is possible to produce a bovine mammary-associated serum
amyloid (M-SAA) protein at levels above 5% of TSP in the
chloroplasts of a photosynthetic strain. M-SAA is found in
the colostrum of mammals and can induce mucin synthesis
in mammalian gut epithelial cells, which could offer protec-
tion against intestinal bacterial and viral infections in new-
borns. M-SAA accumulated predominantly as a soluble
protein and was shown to be bioactive when assessed by
the induction of mucin in a human intestinal epithelial cell
line (HT29) in vitro.
Manuell et al. (2007) have also demonstrated the in-
fluence of the product of the psbA gene in the expres-
sion of genes driven by the psbA promoter. When
M-SAA was expressed from the psbA promoter in a
non-photosynthetic strain (that is a line lacking the
psbA gene) the protein accumulated to 3% TSP. When
photosynthesis was restored by introduction of a psbA
gene under the control of a psbA promoter, M-SAA did
not accumulate. Interestingly, M-SAA accumulated up
to 5% of TSP (12% total protein) when photosynthesis
was restored by using the psbA gene under the control
of the psbD promoter. As in both cases the D1 protein
was present, there seemed to be a competition between
the psbA mRNA and the M-SAA mRNA for translation
(in which the psbA mRNA was favoured). Other re-
ports have also shown that high levels of protein can
accumulate from the psbA promoter when the en-
dogenous psbA gene has been deleted (Rasala et al.
2010).
The second report for a human protein produced in
the chloroplast of C. reinhardtii was for Glutamic Acid
Decarboxylase 65 (hGAD65), which is a key autoantigen
in insulin dependent diabetes mellitus (IDDM) (Wang
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ant marker for the prediction and diagnosis of type 1
diabetes, as antibodies against it are present before the
onset of the disease and it is believed that tolerance to
this autoantigen can be induced using a vaccination-like
scheme. Wang et al. (2008) transformed the chloroplast
of C. reinhardtii with the native non codon-optimized
hGAD65 gene under control of the chloroplast rbcL pro-
moter. The presence of hGAD65 was confirmed by
western blotting using anti-GAD antibodies and the level
of accumulation accounted for up to 0.3% TSP, a signifi-
cantly higher value when compared to the 0.04% TSP
obtained for a nuclear transgenic plant (Avesani et al.
2010). The antigenicity of algal-derived hGAD65 was de-
termined by its immunoreactivity with sera from diabetic
patients.
In an extensive study, Rasala et al. (2010) evaluated
the expression of a diverse group of therapeutic human
proteins in C. reinhardtii chloroplast. Four out of the
seven proteins reported in the study accumulated to
levels above 1% TSP. All four proteins 10FN3, 14FN3,
HMGB1, and VEGF were expressed using the psbA and
atpA promoters and were shown to be biologically ac-
tive. In a follow up report, (Rasala et al. 2011) reported
the expression of 14FN3, a potential antibody mimic,
using a line that lacked the psbA gene, and hence, was
non-photosynthetic. Lines expressing the 14FN3 from
the wild-type psbA promoter and from a chimeric pro-
moter (obtained by fusing the 16S rDNA promoter and
the psbA 5’UTR) were generated. In parallel, using a
photosynthetically active strain, the psbD, atpA, and the
chimeric16S rDNA + atpA 5′UTR promoters driving the
expression of 14FN3 were used to generate transplas-
tomic lines. The wild type psbA promoter allowed for
the accumulation of 14FN3 to 0.5% TSP but only in the
non-photosynthetic strain. The chimeric 16S + atpA and
16S + psbA promoters also yielded significant amounts
of the heterologous protein in photosynthetic strains,
0.23% and 0.21% respectively. Finally, the wild type atpA
and psbD promoters supported only low levels of ex-
pression for 14FN3.
Proteins with enzymatic activity intended for animal
use have also been produced in the chloroplast of C.
reinhardtii (Yoon et al. 2011). Nine versions of a phy-
tase gene of bacterial or fungal origin were used to gen-
erate transplastomic lines. Microbial phytases are used
as food additives to increase phosphorus utilization
from phytate in the livestock industry with the aim of
reducing fecal phytates and inorganic phosphate (iP)
outputs. (Yoon et al. 2011) recovered transplastomic
algae but only in the case of strain where a full-length,
codon-optimized version of the E. coli appA gene (E-OPT)
phytase was used, enzymatic activity could be detected
(10 U/g of algae).Strains of algae expressing the enzyme phytase were
lyophilized and directly added as a food additive, termed
Chlasate, to deliver the enzyme with no need of purifica-
tion. Using this transgenic phytase at 500 U/kg in the
diet of young broiler chicks, the fecal phytate excretion
was reduced by 43% while the assimilation of iP in-
creased to 41%, as compared to those of chicks fed with
only the basal diet. The effectiveness of Chlasate to
break down the dietary phytates was comparable with
that of a commercial fungal phytase.
To make the final product, cell pastes were directly
frozen once with liquid nitrogen, thawed, frozen again
and dried with a lyophilizer to obtain a dry cell powder.
The one-step frozen-thawing procedure seemed to be
sufficient to rupture the C. reinhardtii cells and release a
functional phytase. The major advantage of using trans-
genic microalgae for oral delivery is that several process-
ing steps from raw material to the edible final product
can be omitted.
Final remarks and conclusions
It is now clear that chloroplast transformation in C. rein-
hardtii can be consistently accomplished and used to
generate transplastomic strains that accumulate recombin-
ant heterologous proteins with therapeutical applications.
Although it is still behind the achievements chloroplast
transformation has had in land plants has had (Daniell
et al. 2009), the technology has successfully been used in
laboratories around the world to produce diverse bacterial,
viral, and human proteins.
To achieve high levels of foreign protein accumulation,
diverse endogenous and chimeric promoters have been
developed. In some cases, recombinant proteins have ac-
cumulated up to 20% of the TSP (Surzycki et al. 2009),
although 1-5% TSP is the most common accumulation
range for several proteins (Manuell et al. 2007; Rasala
et al. 2010). In some other cases low to undetectable
levels of protein accumulation have been encountered
(Rasala et al. 2010; Surzycki et al. 2009), stressing the
importance of diverse factors in the regulation of gene
expression. At present time there is no way of predicting
which genetic elements would be better suited for the
expression of a particular foreign gene. Some promoters
seem to work and yield reasonable levels of expression
for some genes whilst for others they seem to be less ap-
propriate (Rasala et al. 2010).
For some of the proteins revised in this paper, bio-
logical activity has been evaluated both in vitro and
in vivo. In the case of antigens intended for vaccination,
it has been demonstrated that a systemic and mucosal
response can be induced after the administration of a ly-
ophilized powder of the algae expressing the antigen in
mice. However, after the purity and efficacy of the anti-
gens has been demonstrated, preclinical trials are needed
Almaraz-Delgado et al. AMB Express 2014, 4:57 Page 8 of 9
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gens. Next step would be to carry out clinical trials,
though, this may still be a long way from current status;
chloroplast-derived vaccines from plants have had a tor-
tuous path from the laboratory to clinical trials (Rybicki
2009). It is clear that the ultimate goal of producing pro-
teins in the chloroplast of C. reinhardtii cannot be con-
sidered accomplished until there is an algal produced
protein in the market.
Besides being used as bioreactors for the production of
recombinant proteins, C. reinhardtii and algae in general,
have the potential of serving as tools to solve diverse prob-
lems. The spectrum of metabolites that could potentially
be produced in the chloroplast of C. reinhardtii by genetic
modification goes from secondary metabolites such as vi-
tamins, carotenoids, and oils to bioplastics and biofuels
(such as hydrogen, fatty acids, or solvents), etc. This would
alleviate two problems, the ever-increasing worry of a de-
cline in oil production and a reduction in atmospheric
CO2. Use of algae in bioremediation, removal of toxic
compounds from land, water, and air has also been con-
templated but poorly studied.
Also, there is a need to expand chloroplast transform-
ation technology to other algae species. Such species
should be: 1) easily scalable, with a better ability to grow
in open ponds or photobioreactors and, 2) grow faster
and have little susceptibility to contamination, but most
importantly, 3) strains that depending on the final use
are valuable for the production of biopharmaceuticals,
secondary metabolites or high energy molecules, such as
lipids and sugars. A wide interest in such strains will
detonate the development of genetic tools and trans-
formation methods, which has been so far limited to C.
reinhardtii.
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